Open Access<p>Clinical Outcome of Systemic Treatment for Advanced Soft Tissue Sarcoma: Real-Life Perspective in Japan</p>
Author(s) -
Tomoki Nakamura,
Kunihiro Asanuma,
Tomohito Hagi,
Akihiro Sudo
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s275526
Subject(s) - medicine , eribulin , trabectedin , soft tissue sarcoma , ifosfamide , pazopanib , sarcoma , doxorubicin , anthracycline , oncology , surgery , chemotherapy , cancer , soft tissue , metastatic breast cancer , breast cancer , etoposide , pathology , sunitinib
The median survival time of patients with advanced soft tissue sarcoma (STS) is typically <12 months. Since 2012, physicians were able to administer second- and/or third-line treatment easily in Japan, following the approval of new drugs, namely, pazopanib, eribulin, and trabectedin. We investigated the real-life experience of adults with advanced STS who received systemic therapy after the approval of the aforementioned new drugs.